Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Eloxatin approved for first-line treatment of advanced colorectal cancer

Jan. 15, 2004

BMS scientists claim Eg5 inhibitors and their use in cancer therapy

Jan. 15, 2004

Pierre Fabre presents protein prenyltransferase inhibitors for cancer and other disorders

Jan. 15, 2004

A new phase II clinical trial to evaluate Davanat with 5-FU in refractory colorectal cancer

Jan. 14, 2004

Widespread use of alternative medicine in prostate cancer patients

Jan. 14, 2004

IND filed for phase I ThermoDox trial for liver cancer

Jan. 14, 2004

Approval granted to an expanded use of Eloxatin for metastatic colorectal cancer in Europe

Jan. 13, 2004

Phase I/II trial of MTC-MMC in NSCLC cleared to begin

Jan. 13, 2004

New protein kinase inhibitors and their use in cancer therapy reported by Cytopia

Jan. 13, 2004

Novel KSP inhibitors identified by Merck researchers

Jan. 13, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 5, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...